Calithera
Biosciences Inc (NASDAQ:CALA)
closed gained by 28.66% to 29.85, Calithera told investors Monday its cancer
treatment CB-839 showed "significant anti-tumor efficacy" in a
pre-clinical study.
The data was
presented at the American Society of Hematology meeting in San Francisco, where
the organization also offered promising interim results from a Phase I clinical
study of the drug in treating breast cancer.
Calithera Biosciences, Inc. (CALA) was a big mover last
session, as the organization saw its shares rise by nearly 30% on the day. The
move came on solid volume too with far more shares changing hands than in a
normal session. This continues the recent uptrend for the company as the stock
is now up 101.05% since Dec 1, 2014.
Calithera Biosciences is a
clinical-stage company focused on discovering and developing novel small
molecule drugs directed against tumor metabolism and tumor immunology.
Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of
glutaminase, a critical enzyme in tumor metabolism, and is currently being
tested in patients with solid and hematological cancers.
0 comments:
Post a Comment